EMA panel recommends that use of Actelion's Uptravi may continue
ZURICH, Feb 10 (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used in line with current prescription information amid a probe into five deaths in France among those using the pulmonary arterial hypertension medicine.
(Reporting by John Miller; Editing by Michael Shields)